Publications by authors named "B K Felber"
Article Synopsis
- IL-15 agonists are promising immunotherapy options as they boost the growth of immune cells like natural killer (NK) and CD8 T cells, but they have a short duration in the body requiring frequent doses.
- A new approach using hydrogel microspheres (MS) was developed to extend the half-life of IL-15, which successfully increased its duration to about one week.
- The study found that the MS conjugate of another IL-15 agonist, RLI, had a shorter half-life of 30 hours and was effective in stimulating immune cells, but caused significant injection-site toxicity; thus, it was focused on for intra-tumoral therapy where such effects could be potentially beneficial.
BACKGROUNDAn HIV-1 DNA vaccine composed of 7 highly conserved, structurally important elements (conserved elements, CE) of p24Gag was tested in a phase I randomized, double-blind clinical trial (HVTN 119, NCT03181789) in people without HIV. DNA vaccination of CE prime/CE+p55Gag boost was compared with p55Gag.METHODSTwo groups (n = 25) received 4 DNA vaccinations (CE/CE+p55Gag or p55Gag) by intramuscular injection/electroporation, including IL-12 DNA adjuvant.
View Article and Find Full Text PDFArticle Synopsis
- Cytokines and chemokines are important for our immune system, especially after getting vaccinated against COVID-19 with the BNT162b2 mRNA vaccine.
- Researchers studied how these substances in the body respond after people received their third dose of the vaccine, comparing it to responses after the first and second doses.
- They found that some immune responses lasted longer after the third dose and were linked to making more antibodies that help fight off the virus.
Objective: The primary objective of the study was to assess the immunogenicity of an HIV-1 Gag conserved element DNA vaccine (p24CE DNA) in people with HIV (PWH) receiving suppressive antiretroviral therapy (ART).
Design: AIDS Clinical Trials Group A5369 was a phase I/IIa, randomized, double-blind, placebo-controlled study of PWH receiving ART with plasma HIV-1 RNA less than 50 copies/ml, current CD4 + T-cell counts greater than 500 cells/μl, and nadir CD4 + T-cell counts greater than 350 cells/μl.
Methods: The study enrolled 45 participants randomized 2 : 1 : 1 to receive p24CE DNA vaccine at weeks 0 and 4, followed by p24CE DNA admixed with full-length p55 Gag DNA vaccine at weeks 12 and 24 (arm A); full-length p55 Gag DNA vaccine at weeks 0, 4, 12, and 24 (arm B); or placebo at weeks 0, 4, 12, and 24 (arm C).
Transmitted/founder (TF) simian-human immunodeficiency viruses (SHIVs) express HIV-1 envelopes modified at position 375 to efficiently infect rhesus macaques while preserving authentic HIV-1 Env biology. SHIV.C.
View Article and Find Full Text PDF